Touchlight launches mbDNA circular single-stranded DNA platform for enhanced gene editing applications
Touchlight, a cell-free DNA innovation company, has announced the commercial launch of mbDNA™ (megabulb DNA), a novel circular single-stranded DNA platform designed to improve non-viral gene editing efficiency across diverse cell types.
Novel architecture addresses existing limitations
The mbDNA platform features a customisable stem region with fully user-defined sequences free of phage or bacterial elements. This circular single-stranded DNA structure supports gene insertions ranging from 1-20kb whilst maintaining high cell viability, addressing key limitations of traditional adeno-associated virus (AAV) vectors.
“Following extensive beta testing with key opinion leaders, CDMOs and pharmaceutical partners, we are proud to officially launch mbDNA to the market,” said Jill Makin, CSO at Touchlight.
The platform has demonstrated superior knock-in efficiency compared to double-stranded DNA and competitor single-stranded DNA formats. According to the company, mbDNA consistently achieves knock-in rates of 75% in primary human T cells, with GMP manufacturing capabilities planned for the near future.
Versatile delivery methods support clinical translation
mbDNA functions as a high-efficiency template for homology-directed repair (HDR) and is compatible with multiple delivery methods including electroporation, nucleofection, and lipid nanoparticle formulations. The platform can also serve as an episomal expression vector in transient non-viral gene therapy applications, potentially offering improved tolerability due to its single-stranded nature.
Manufacturing advantages over traditional vectors
Non-viral DNA platforms like mbDNA offer greater design flexibility compared to AAV vectors, which face restrictions including limited payload capacity, high manufacturing costs, and extended production timelines. Touchlight’s enzymatic DNA production process provides a scalable alternative that can accommodate the growing demands of genetic medicine development.
Regulatory and commercial status
Touchlight holds an FDA Drug Master File accepted in 2022 and received the world’s first cell-free DNA GMP licence in 2025. The company’s enzymatic DNA technology supports various applications including AAV production, mRNA therapeutics, DNA vaccines, and gene editing platforms. Multiple client products utilising Touchlight’s technology are already in clinical development.
The London-based company, founded in 2007, positions itself as a leading contract development and manufacturing organisation (CDMO) specialising in enzymatic GMP DNA production for genetic medicine applications.
For more information, visit: https://touchlight.com/mbdna-the-smarter-dna-for-non-viral-gene-editing/
Digital issue: Please click here for more information
